MA38253B1 - Compositions comprenant de la vortioxétine et du donépézil - Google Patents

Compositions comprenant de la vortioxétine et du donépézil

Info

Publication number
MA38253B1
MA38253B1 MA38253A MA38253A MA38253B1 MA 38253 B1 MA38253 B1 MA 38253B1 MA 38253 A MA38253 A MA 38253A MA 38253 A MA38253 A MA 38253A MA 38253 B1 MA38253 B1 MA 38253B1
Authority
MA
Morocco
Prior art keywords
compositions
vortioxetine
donepezil
treatment
relates
Prior art date
Application number
MA38253A
Other languages
English (en)
Other versions
MA38253A1 (fr
Inventor
Connie Sanchez Morillo
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of MA38253A1 publication Critical patent/MA38253A1/fr
Publication of MA38253B1 publication Critical patent/MA38253B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des compositions pharmaceutiques comprenant de la vortioxétine et du donépézil, et l'utilisation de ces compositions pour le traitement de dysfonctionnements cognitifs.
MA38253A 2012-12-13 2013-12-12 Compositions comprenant de la vortioxétine et du donépézil MA38253B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261736799P 2012-12-13 2012-12-13
PCT/EP2013/076337 WO2014090929A1 (fr) 2012-12-13 2013-12-12 Compositions comprenant de la vortioxétine et du donépézil

Publications (2)

Publication Number Publication Date
MA38253A1 MA38253A1 (fr) 2017-02-28
MA38253B1 true MA38253B1 (fr) 2017-10-31

Family

ID=49943326

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38253A MA38253B1 (fr) 2012-12-13 2013-12-12 Compositions comprenant de la vortioxétine et du donépézil

Country Status (44)

Country Link
US (1) US9211288B2 (fr)
EP (1) EP2931276B1 (fr)
JP (1) JP6257641B2 (fr)
KR (1) KR102171152B1 (fr)
CN (1) CN104853755B (fr)
AP (1) AP2015008498A0 (fr)
AR (2) AR093939A1 (fr)
AU (1) AU2013357308B2 (fr)
BR (1) BR112015013675B1 (fr)
CA (1) CA2893468C (fr)
CL (1) CL2015001615A1 (fr)
CR (1) CR20150303A (fr)
CY (1) CY1120098T1 (fr)
DK (1) DK2931276T3 (fr)
DO (1) DOP2015000133A (fr)
EA (1) EA028300B1 (fr)
EC (1) ECSP15023182A (fr)
ES (1) ES2663680T3 (fr)
GE (1) GEP201706739B (fr)
GT (1) GT201500143A (fr)
HK (1) HK1212601A1 (fr)
HR (1) HRP20180333T1 (fr)
HU (1) HUE036280T2 (fr)
IL (1) IL239192B (fr)
LT (1) LT2931276T (fr)
MA (1) MA38253B1 (fr)
ME (1) ME03029B (fr)
MX (1) MX362886B (fr)
MY (1) MY171802A (fr)
NI (1) NI201500078A (fr)
NO (1) NO2970700T3 (fr)
NZ (1) NZ708595A (fr)
PE (1) PE20151026A1 (fr)
PH (1) PH12015501302A1 (fr)
PL (1) PL2931276T3 (fr)
PT (1) PT2931276T (fr)
RS (1) RS56949B1 (fr)
RU (1) RU2635528C2 (fr)
SG (1) SG11201504483YA (fr)
SI (1) SI2931276T1 (fr)
TN (1) TN2015000235A1 (fr)
UA (1) UA114016C2 (fr)
WO (1) WO2014090929A1 (fr)
ZA (1) ZA201504274B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105218482B (zh) * 2014-06-24 2018-04-06 杭州和泽医药科技有限公司 沃替西汀氢溴酸盐β晶型的制备方法
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
CN105315184B (zh) * 2015-06-26 2017-03-29 上海医药工业研究院 一种沃替西汀的制备方法及其中间体
US10493046B2 (en) * 2015-07-17 2019-12-03 Universite Paris Descartes 5-hydroxytryptamine 1B receptor-stimulating agent for use as a promoter of satellite cells self-renewal and/or differentiation
CN105534933A (zh) * 2016-01-19 2016-05-04 美吉斯制药（厦门）有限公司 一种沃替西汀口腔崩解片及其制备方法
MX2018015759A (es) 2016-07-01 2019-03-21 H Lundbeck As Regimenes de dosificacion de vortioxetina para el rapido inicio del efecto antidepresivo.
WO2018182639A1 (fr) * 2017-03-30 2018-10-04 Rundle Research, LLC Méthodes de traitement de la dépression
US10398691B2 (en) 2017-03-30 2019-09-03 Rundle Research, LLC Methods of treating depression

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0268871A1 (fr) 1986-10-31 1988-06-01 Sumitomo Pharmaceuticals Company, Limited Dérivés de quinoléine
EP0363415B1 (fr) 1987-05-04 2008-10-15 Davis, Bonnie Composes permettant le traitement de la maladie d'alzheimer
IT1225462B (it) 1987-04-03 1990-11-14 Mediolanum Farmaceutici Srl Sali organici di derivati della fisostigmina
EP0403713A1 (fr) 1989-06-22 1990-12-27 Merrell Dow Pharmaceuticals Inc. Inhibiteurs d'acétylcholinestérase
US4914102A (en) 1989-09-28 1990-04-03 Hoechst Roussel Pharmaceuticals, Inc. N-aminocarbamates related to physostigmine, pharmacentical compositions and use
TW200462B (fr) 1990-09-27 1993-02-21 Hoechst Roussel Pharma
US5246947A (en) 1991-09-23 1993-09-21 Hoechst-Roussel Pharmaceuticals Incorporated Substituted pyridinylamino-1,2-benzisothiazoles and their use for treating depression
US5231093A (en) 1991-10-01 1993-07-27 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
ES2042384B1 (es) 1991-12-26 1994-06-01 Boehringer Ingelheim Espana Procedimiento para obtener derivados bis-piridinicos.
SE9302080D0 (sv) 1993-06-16 1993-06-16 Ab Astra New compounds
ES2165586T3 (es) 1996-04-12 2002-03-16 Aventis Pharma Inc Derivados de isatina como inhibidores de acetilcolinesterasa y analgesicos.
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
EP1491531B1 (fr) 2002-03-29 2007-12-26 Eisai R&D Management Co., Ltd. Derive de (1-indanone)-(1,2,3,6-tetrahydropyridine)
PL373903A1 (en) * 2002-05-31 2005-09-19 H.Lundbeck A/S A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
JP2006525226A (ja) * 2002-12-24 2006-11-09 ニューロケム （インターナショナル） リミテッド β−アミロイド関連疾患の治療のための治療用製剤
JP5122445B2 (ja) * 2006-05-08 2013-01-16 帝國製薬株式会社 抗認知症薬物の経皮吸収製剤
MX2008015445A (es) * 2006-06-09 2008-12-12 Wyeth Corp Metodo para mejorar la funcion cognoscitiva.
EA015287B1 (ru) 2006-06-16 2011-06-30 Х. Лундбекк А/С 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазин в качестве соединения с сочетанием активности в отношении повторного захвата серотонина, 5-нти 5-нтдля лечения когнитивного нарушения
WO2009005519A1 (fr) * 2007-06-29 2009-01-08 Accera, Inc. Combinaisons de triglycérides à chaîne moyenne et d'agents thérapeutiques pour le traitement et la prévention de la maladie d'alzheimer et d'autres maladies résultant d'un métabolisme neuronal réduit
TW200932233A (en) 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
TW201033181A (en) 2009-02-17 2010-09-16 Lundbeck & Co As H Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine

Also Published As

Publication number Publication date
AR093939A1 (es) 2015-07-01
NO2970700T3 (fr) 2018-05-26
MA38253A1 (fr) 2017-02-28
EA201590932A1 (ru) 2015-10-30
AU2013357308B2 (en) 2017-08-31
MY171802A (en) 2019-10-30
PH12015501302B1 (en) 2016-02-01
ME03029B (fr) 2018-10-20
KR102171152B1 (ko) 2020-10-29
PE20151026A1 (es) 2015-07-11
KR20150095681A (ko) 2015-08-21
US20150297585A1 (en) 2015-10-22
RU2015122256A (ru) 2017-01-16
HK1212601A1 (zh) 2016-06-17
CA2893468C (fr) 2021-01-12
CL2015001615A1 (es) 2015-08-07
AU2013357308A1 (en) 2015-06-18
JP6257641B2 (ja) 2018-01-10
ES2663680T3 (es) 2018-04-16
UA114016C2 (xx) 2017-04-10
ECSP15023182A (es) 2015-12-31
JP2016502990A (ja) 2016-02-01
IL239192A0 (en) 2015-07-30
US9211288B2 (en) 2015-12-15
CR20150303A (es) 2016-07-07
RS56949B1 (sr) 2018-05-31
TN2015000235A1 (en) 2016-10-03
HUE036280T2 (hu) 2018-06-28
NI201500078A (es) 2016-02-15
LT2931276T (lt) 2018-04-10
CA2893468A1 (fr) 2014-06-19
MX2015007269A (es) 2015-08-12
DK2931276T3 (en) 2018-03-26
HRP20180333T1 (hr) 2018-04-06
PL2931276T3 (pl) 2018-06-29
CN104853755B (zh) 2017-08-22
EA028300B1 (ru) 2017-10-31
NZ708595A (en) 2019-06-28
CN104853755A (zh) 2015-08-19
EP2931276A1 (fr) 2015-10-21
GT201500143A (es) 2016-01-22
MX362886B (es) 2019-02-22
CY1120098T1 (el) 2018-12-12
DOP2015000133A (es) 2015-11-30
GEP201706739B (en) 2017-09-25
WO2014090929A1 (fr) 2014-06-19
PT2931276T (pt) 2018-03-19
ZA201504274B (en) 2016-11-30
SG11201504483YA (en) 2015-07-30
EP2931276B1 (fr) 2018-02-21
RU2635528C2 (ru) 2017-11-13
IL239192B (en) 2019-03-31
SI2931276T1 (en) 2018-05-31
AP2015008498A0 (en) 2015-05-31
PH12015501302A1 (en) 2016-02-01
BR112015013675B1 (pt) 2022-04-26
AR125920A2 (es) 2023-08-23
BR112015013675A2 (pt) 2017-07-11

Similar Documents

Publication Publication Date Title
MA41013A (fr) Compositions comprenant des souches bactériennes
MA38253A1 (fr) Compositions comprenant de la vortioxétine et du donépézil
MA41060A (fr) Compositions comprenant des souches bactériennes
MA55434B1 (fr) Compositions comprenant des souches bactériennes
MA41010B1 (fr) Compositions comprenant des souches bactériennes
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
EA201590165A1 (ru) Сдерживающие злоупотребление фармацевтические композиции для контролируемого высвобождения
EA201491009A1 (ru) Гель лизата тромбоцитов
PH12014501991B1 (en) Phenicol antibacterials
MA41977B1 (fr) Imidazopyrazinones utilisées comme inhibiteurs de pde1
EA201692007A1 (ru) Соединения изоиндолинона в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных с ними нарушений
UA113538C2 (xx) Фторметил-5,6-дигідро-4h-$1,3]оксазини
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
MX2017004808A (es) Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple.
EA201792575A1 (ru) Фармацевтические композиции леветирацетама пролонгированного высвобождения
EA201791009A1 (ru) Композиции, содержащие циклоспорин
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
IN2015DN02501A (fr)
MA39837B1 (fr) Quinazoline-thf-amines halogénées en tant qu'inhibiteurs de la pde1
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
MX2015014657A (es) Nuevos agentes antibacterianos de fenicol.
FR3010635B1 (fr) Compositions pharmaceutiques a base d'agent filmogene pour le traitement de l'hyposialie
EA201401142A1 (ru) Замещенные 6-аминоникотинамиды, несущие он-содержащую группу, в качестве модуляторов kcnq2/3
TN2014000484A1 (en) Dronedarone for use in leishmaniasis, formulations and associations for use in leishmaniasis.